Selective allosteric inhibition of Tyk2 seems to avoid some adverse events (dyslipidemia, laboratory abnormalities, thromboembolic events, cancer, or severe infections) that have been observed in some populations of patients treated with non-selective Jak inhibitors, mostly for rheumatological indications. Here, TYK2 is linked to metabolic syndrome.